A-HYDROCORT SUMMARY
A-Hydrocort sterile powder contains hydrocortisone sodium succinate as the active ingredient. Hydrocortisone sodium succinate, is a white, or nearly white, odorless, hygroscopic, amorphous solid. It is very soluble in water and in alcohol, very slightly soluble in acetone and insoluble in chloroform.
When oral therapy is not feasible, and the strength,
dosage form and route of administration of the drug reasonably lend
the preparation to the treatment of the condition, A-Hydrocort sterile
powder is indicated for intravenous or intramuscular use in the following
conditions:
1. Endocrine
Disorders
-
Primary or secondary adrenocortical insufficiency
(hydrocortisone or cortisone is the drug of choice; synthetic analogs
may be used in conjunction with mineralocorticoids where applicable;
in infancy, mineralocorticoid supplementation is of particular importance)
-
Acute adrenocortical insufficiency (hydrocortisone
or cortisone is the drug of choice; mineralocorticoid supplementation
may be necessary, particularly when synthetic analogs are used)
-
Preoperatively and in the event of serious trauma
or illness, in patients with known adrenal insufficiency or when adrenocortical
reserve is doubtful
-
Shock unresponsive to conventional therapy if adrenocortical
insufficiency exists or is suspected
-
Congenital adrenal hyperplasia
-
Hypercalcemia associated with cancer
-
Nonsuppurative thyroiditis
2. Rheumatic Disorders
As adjunctive therapy for short-term
administration (to tide the patient over an acute episode or exacerbation)
in:
-
Post-traumatic osteoarthritis
-
Synovitis of osteoarthritis
-
Rheumatoid arthritis, including juvenile rheumatoid
arthritis (selected cases may require low-dose maintenance therapy)
-
Acute and subacute bursitis
-
Epicondylitis
-
Acute nonspecific tenosynovitis
-
Acute gouty arthritis
-
Psoriatic arthritis
-
Ankylosing spondylitis
3. Collagen Diseases
During an exacerbation or as maintenance
therapy in selected cases of:
4. Dermatologic Diseases
-
Pemphigus
-
Severe erythema multiforme (Stevens-Johnson syndrome)
-
Exfoliative dermatitis
-
Bullous dermatitis herpetiformis
-
Severe seborrheic dermatitis
-
Severe psoriasis
-
Mycosis fungoides
5. Allergic States
Control of severe or incapacitating allergic
conditions intractable to adequate trials of conventional treatment
in:
-
Bronchial asthma
-
Contact dermatitis
-
Atopic dermatitis
-
Serum sickness
-
Seasonal or perennial allergic rhinitis
-
Drug hypersensitivity reactions
-
Urticarial transfusion reactions
-
Acute noninfectious laryngeal edema (epinephrine
is the drug of first choice)
6. Ophthalmic Diseases
Severe acute and chronic allergic and
inflammatory processes involving the eye, such as:
-
Herpes zoster ophthalmicus
-
Iritis, iridocyclitis
-
Chorioretinitis
-
Diffuse posterior uveitis and choroiditis
-
Optic neuritis
-
Sympathetic ophthalmia
-
Anterior segment inflammation
-
Allergic conjunctivitis
-
Allergic corneal marginal ulcers
-
Keratitis
7. Gastrointestinal
Diseases
To tide the patient
over a critical period of the disease in:
8. Respiratory Diseases
9. Hematologic Disorders
-
Acquired (autoimmune) hemolytic anemia
-
Idiopathic thrombocytopenic purpura in adults (IV
only; IM administration is contraindicated)
-
Secondary thrombocytopenia in adults
-
Erythroblastopenia (RBC anemia)
-
Congenital (erythroid) hypoplastic anemia
10. Neoplastic Diseases
For palliative management of:
11. Edematous States
To induce diuresis or remission of proteinuria
in the nephrotic syndrome, without uremia, of the idiopathic type
or that due to lupus erythematosus
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
|
|
NEWS HIGHLIGHTS
Published Studies Related to A-Hydrocort (Hydrocortisone)
Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy
subjects. [2015] 3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a popular recreational
drug. The aim of the present study was to explore the role of dopamine in the
psychotropic effects of MDMA using bupropion to inhibit the dopamine and
norepinephrine transporters through which MDMA releases dopamine and
norepinephrine by investigating.
Continuous Subcutaneous Hydrocortisone Infusion Therapy in Addison's Disease: A
Randomized, Placebo-Controlled Clinical Trial. [2014] CONCLUSIONS: Biochemical measurements indicate similar cortisol exposure during
Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in
children: a randomized clinical trial. [2014] IMPORTANCE: Alopecia areata is an idiopathic cause of hair loss with limited
therapeutic repertoire. OBJECTIVE: To compare the efficacy and safety of a high- vs low-potency topical
corticosteroid in pediatric patients...
Randomised controlled trial of the effects of L-ornithine on stress markers and
sleep quality in healthy workers. [2014] CONCLUSION: L-ornithine supplementation has the potential to relieve stress and
Effects of Jitai tablet, a traditional Chinese medicine, on plasma
adrenocorticotropic hormone and cortisol levels in heroin addicts during
abstinence. [2014] cortisol in heroin addicts given Jitai tablet treatment during abstinence... CONCLUSIONS: Heroin addicts could respond to Jitai tablets through changes in the
Clinical Trials Related to A-Hydrocort (Hydrocortisone)
The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism [Recruiting]
This study aims at assessing the effect of today's standard of hydrocortisone dosage versus
previous hydrocortisone dosage on flexibility and partitioning of ectopic lipid depots (IMCL
and IHCL) after a standardised fat load followed by a short-term aerobic exercise in
patients with corticotropic pituitary insufficiency.
Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia [Recruiting]
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia [Completed]
This study will test a new, extended release form of hydrocortisone called Chronocort in
patients with congenital adrenal hyperplasia (CAH). People with CAH do not make enough of
the adrenal hormones cortisol and aldosterone, and their adrenal glands make too much of the
sex hormone androgen. Medicines called glucocorticoids (hydrocortisone, dexamethasone and
prednisone) are currently used to treat CAH, but finding the best dose of these drugs that
effectively lowers androgens without causing undesirable side effects, such as weight gain
and slow growth rate in children, is often difficult to achieve.
Adolescents and adults with CAH due to 21-hydroxylase deficiency may be eligible for this
study. Children 16 years of age and older are eligible with confirmation by bone age that
they are no longer growing.
Participants undergo the following tests and procedures during two inpatient visits one
month apart at the NIH Clinical Center:
- Medical history and physical examination.
- Medications: Following 7 days of Cortef (standard drug treatment for CAH), patients
begin taking Chronocort on day 3 of hospitalization and continue the tablets once a day
for 1 month.
- Blood tests: A catheter (plastic tube) is inserted in a vein and left in place for
frequent blood draws in order to avoid repeated needlesticks. Blood is drawn for
chemistries, blood count, pregnancy test in women, and for serial tests (up to 26
samples in a 24-hour period) to measure hormone levels.
- 24-hour urine test.
- Height and weight measurements.
Between the two hospitalizations, patients are contacted by NIH weekly to check for possible
side effects from Chronocort. Two weeks after the first visit, patients also will have blood
drawn by their regular doctor or a local clinic. A few days before the second
hospitalization, patients undergo a 20-minute telephone questionnaire about energy level and
well being.
About 30 days after discharge from the second hospitalization, patients are followed up with
a telephone call to see how they are doing.
Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency [Completed]
This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase
II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral
modified-release hydrocortisone in comparison to conventional thrice-daily oral
hydrocortisone tablets in patients with adrenal insufficiency
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration [Completed]
The current study will test the causal relationship between elevated levels of cortisol and
the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to
environmental threat. The investigators predict that carriers of the short allele of the
serotonin transporter gene who have elevated cortisol levels will be most sensitive to
threatening environments, whereas carriers of the long allele who do not have elevated
cortisol (placebo subjects) will be least sensitive.
|
|
Page last updated: 2015-08-10
|